Last reviewed · How we verify
TAF/FTC
TAF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.
TAF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (as part of combination antiretroviral therapy).
At a glance
| Generic name | TAF/FTC |
|---|---|
| Sponsor | Göteborg University |
| Drug class | Nucleoside reverse transcriptase inhibitor combination |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Tenofovir alafenamide (TAF) and emtricitabine (FTC) are both nucleoside reverse transcriptase inhibitors (NRTIs) that work synergistically to inhibit HIV reverse transcriptase, an enzyme essential for viral replication. TAF is a prodrug that delivers tenofovir to infected cells with improved intracellular activation and reduced systemic exposure compared to tenofovir disoproxil fumarate (TDF). The combination is used as part of antiretroviral therapy regimens to suppress HIV viral load.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Rash
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 (PHASE2, PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks (PHASE4)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAF/FTC CI brief — competitive landscape report
- TAF/FTC updates RSS · CI watch RSS
- Göteborg University portfolio CI